Education
About Us
Working with TipRanks
Follow Us
Financiere de Tubize SA (DE:FTD)
FRANKFURT:FTD
FTD Stock Chart & Stats
€225.00
€1.40(0.96%)
At close: 4:00 PM EST
€225.00
€1.40(0.96%)
Day’s Range― - ―
52-Week Range€106.60 - €238.50
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€10.02B
Enterprise Value€5.92B
Total Cash (Recent Filing)€462.00K
Total Debt (Recent Filing)€86.50M
Price to Earnings (P/E)108.0
Beta0.73
Next Earnings
Mar 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.15
Shares Outstanding44,512,600
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Financiere de Tubize News
FTD FAQ
What was Financiere de Tubize SA’s price range in the past 12 months?
Financiere de Tubize SA lowest stock price was €106.60 and its highest was €238.50 in the past 12 months.
What is Financiere de Tubize SA’s market cap?
Financiere de Tubize SA’s market cap is €10.02B.
When is Financiere de Tubize SA’s upcoming earnings report date?
Financiere de Tubize SA’s upcoming earnings report date is Mar 21, 2026 which is in 38 days.
How were Financiere de Tubize SA’s earnings last quarter?
Financiere de Tubize SA released its earnings results on Aug 02, 2025. The company reported €2.147 earnings per share for the quarter, beating the consensus estimate of N/A by €2.147.
Is Financiere de Tubize SA overvalued?
According to Wall Street analysts Financiere de Tubize SA’s price is currently Overvalued.
Does Financiere de Tubize SA pay dividends?
Financiere de Tubize SA does not currently pay dividends.
What is Financiere de Tubize SA’s EPS estimate?
Financiere de Tubize SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Financiere de Tubize SA have?
Financiere de Tubize SA has 44,512,600 shares outstanding.
What happened to Financiere de Tubize SA’s price movement after its last earnings report?
Financiere de Tubize SA reported an EPS of €2.147 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.361%.
Which hedge fund is a major shareholder of Financiere de Tubize SA?
Currently, no hedge funds are holding shares in DE:FTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Financiere de Tubize SA
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Technical Analysis
Options Prices
Currently, No data available
---